Compounded Tirzepatide weight-loss results
Compounded Tirzepatide produced 22.5% mean body-weight reduction in the SURMOUNT-1 pivotal trial at 72 weeks — substantially more than placebo and competitive with other approved weight-loss medications. This page details the clinical evidence, eligibility criteria, and what individual results look like in practice.
How effective is Compounded Tirzepatide?
Mean body-weight change at 72 weeks in the SURMOUNT-1 trial. Source: FDA prescribing information.
Individual results vary. Trial participants also received lifestyle counseling. Full disclaimer.
Expected weight-loss curve
Mean body-weight change across 72 weeks on Compounded Tirzepatide from the SURMOUNT-1 trial. Curve smoothed from published endpoints; individual results vary significantly.
Trial participants also received lifestyle counseling. Real-world results depend on dose adherence, side-effect tolerance, and lifestyle factors.
Eligibility criteria
Who Compounded Tirzepatide is for — and not for
Often a fit for
- Adults with type 2 diabetes (Mounjaro indication)
- Adults with BMI ≥30, or ≥27 with weight-related condition (Zepbound)
- Patients tolerating injection-based therapy
- Patients committed to lifestyle + medication combination
Not appropriate if
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or planning pregnancy
- Type 1 diabetes
- Severe gastrointestinal disease (e.g. gastroparesis)
Eligibility is determined by a licensed prescriber, not GLP1Zoom. See our medical disclaimer.
What individual results actually look like
Trial averages obscure huge individual variation. In SURMOUNT-1:
- The average participant lost ~22.5% of body weight
- About 1 in 3participants lost >15% body weight
- About 1 in 10participants lost <5% (low responders)
- A small percentage gained weight or had no change
Predictors of better response include: starting BMI ≥ 35, adherence to dose schedule, concurrent lifestyle changes (reduced caloric intake, regular activity), and patient commitment to long-term treatment. Predictors of worse response include: dose reductions from side effects, sporadic adherence, and certain genetic variations under research.
Timing — when results show up
Early appetite reduction begins within 1-2 weeks of starting Compounded Tirzepatide. Visible weight loss usually starts at 4-8 weeks after reaching the second titration dose. Maximum effect plateaus around the trial endpoint timing (typically 56-72 weeks depending on the medication). Without continued treatment, regain occurs gradually — most patients regain 2/3 of lost weight within 1 year of stopping.
Compounded Tirzepatide vs other weight-loss approaches
Compared to other options:
- vs lifestyle alone (diet+exercise): typical lifestyle programs produce 3-8% weight loss. Compounded Tirzepatide produces 22.5% — 2-4x more.
- vs older weight-loss medications (phentermine, orlistat): produce ~5-7%. Compounded Tirzepatide substantially outperforms.
- vs bariatric surgery: surgery typically produces 25-35% weight loss, permanent. Compounded Tirzepatide produces 22.5% with risk of regain on stopping. Surgery is more effective but irreversible.
Side effects affecting weight-loss outcomes
Side effects affect how much weight a patient actually loses:
- Patients who reach the target dose with manageable side effects achieve maximum benefit
- Patients who must stay at a lower-than-target dose (due to intolerable side effects) typically lose less weight
- Patients who discontinue early due to side effects often regain rapidly
See our Compounded Tirzepatide side effects guide for management tactics that improve adherence.
Long-term outlook — what happens after a year?
Most clinical data for Compounded Tirzepatide covers 56-72 weeks. Longer-term safety and effectiveness data is accumulating. Key questions still being answered: Is the weight loss maintained at 2-5 years? Are there long-term safety signals not visible in 18-month trials? What happens to insulin sensitivity, cardiovascular events, and other outcomes long-term? Current guidance: treat Compounded Tirzepatide as a long-term medication (years), not a short course.
FAQ about Compounded Tirzepatide for weight loss
How fast does Compounded Tirzepatide work for weight loss?
Appetite reduction within 1-2 weeks; visible weight loss usually 4-8 weeks; maximum effect at 72 weeks per trial data.
Will I regain weight if I stop Compounded Tirzepatide?
Most patients regain about 2/3 of lost weight within 1 year of stopping, based on extension studies. This is why Compounded Tirzepatide is typically treated as a long-term medication rather than a short course.
What if Compounded Tirzepatide doesn't produce enough weight loss for me?
About 10% of patients are low responders (<5% weight loss at full dose). Options include: switching to a different GLP-1 (tirzepatide tends to produce more weight loss than semaglutide), adding adjunct therapy, or considering bariatric surgery if BMI warrants. See our alternatives guide.
Editorial summary based on FDA-approved trial data. Individual results vary. Full disclaimer.